Shots:

• The US FDA has lifted the clinical hold on the rusfertide development program & allow to resume patient dosing in clinical studies of rusfertide
• The company provides the information to the FDA on the basis of complete response & also give patient clinical safety reports & update the investigator brochure- patient informed consent forms- safety database- and included new safety and stopping rules in the study protocols
• The company plans to start P-III registrational study for polycythemia in Q1’22 & will continue to work with the FDA to ensure patient safety

  | Ref: Protagonist | Image: PR Newswire